Comorbid Conditions in Child and Adolescent Patients Diagnosed with Attention Deficit/Hyperactivity Disorder by Yüce, Murat et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Comorbid Conditions in Child and Adolescent Patients
Diagnosed with Attention Deficit/Hyperactivity
Disorder
Murat Yüce, Filiz Uçar and Gökçe Nur Say
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/61112
Abstract
Attention deficit/hyperactivity disorder (ADHD) is one of the most common
childhood psychiatric disorders. The worldwide prevalence of ADHD in children has
been reported at 4-7%. Numerous population- and clinical-based studies have
reported that more than half of cases of ADHD have at least one psychiatric comor‐
bidity. The presence of psychiatric comorbidities complicates the diagnosis, treat‐
ment, and prognosis of ADHD; thus, diagnosis of comorbidities is of great importance.
Possible comorbidities should therefore be investigated in cases diagnosed with
ADHD before treatment planning.
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1. Introduction
Attention deficit/hyperactivity disorder (ADHD) is one of the most common childhood
psychiatric disorders. This disorder is multifactorial in origin and clinically heterogeneous,
leads to socioeconomic burdens, and has undesirable academic and occupational outcomes [1].
The worldwide prevalence of ADHD in children is reported to be 4-7% [2]. Results of long-
term studies have revealed that a substantial proportion of individuals suffering from ADHD
during childhood continue to exhibit symptoms of ADHD during adolescence and adulthood
[2, 3]. Numerous population-based and clinical studies have reported that more than half of
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the patients suffering from ADHD have at least one psychiatric comorbidity and that this rate
increases with age [4-6].
These  comorbidities  may be  different  manifestations  of  the  same disorder  or  may have
different diagnoses while sharing a common disposition. Similarly, ADHD may be an early
manifestation of another disorder and may place the individual at risk of developing the
same [7].
These comorbid psychiatric conditions are more common in boys than in girls [1, 8-11]. One
study conducted in Switzerland reported at least one comorbidity in 87% of the ADHD cases
and more than one comorbidity in 67% [4]. Biederman et al. [7] have reported two or more
comorbidities in 20% of ADHD patients admitted to clinics. A study from Iran found at least
one psychiatric comorbidity in 73% of the childhood and adolescent cases of ADHD [12]. A
clinical study from Turkey also documented the presence of at least one comorbid psychiat‐
ric disorder in 96% of the children diagnosed with ADHD, assessed according to KSADS-
PL [13].
The presence of psychiatric comorbidities complicates the diagnosis, treatment, and prognosis
of ADHD, and thus, the diagnosis of comorbidities is of great importance [14]. Possible
comorbidities should therefore be investigated in patients diagnosed with ADHD before
planning treatment regimens, and the possibility of comorbidities arising during follow-up
should be taken into account [13].
2. Disruptive behavior disorder
Disruptive behavior disorders (DBD) are the most common comorbidities accompanying
ADHD. Individuals with oppositional defiant disorder (ODD) and conduct disorder (CD)
share many characteristics. For example, their conduct is socially unacceptable, they cause
disruption or distress to others more than to themselves (i.e., they “externalize” their prob‐
lems), they are more likely to be male, and they find it difficult to learn from experience. ODD
and CD are commonly investigated together in most studies to highlight their similarities and
differences. Biederman et al. [15] studied the prevalence of comorbidities in children and
adolescents with ADHD aged 6-17 years and reported high rates for ODD (46% in children
and 33% in adolescents) and CD (25% in children and 42% in adolescents).
One study that investigated the effect of gender on the clinical features of ADHD reported that
girls with ADHD are at reduced risk for developing comorbid major depression, conduct
disorder, and oppositional defiant disorder compared to boys with ADHD [16]. In clinical
practice, disruptive behavior disorders have a poorer prognosis when they are comorbid with
ADHD rather than alone and other accompanying comorbid psychiatric disorders. One
population-based prospective study in a broad sample reported an increased risk of unipolar
depression and bipolar disorder in ADHD, and that the risk was greatest in the group with
ADHD and comorbid CD or ODD [17]. ODD is the most common comorbid psychiatric
disorder and is associated with an increase in intrafamilial and social problems, irrespective
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of whether or not CD accompanies ODD [18]. Disruptive behavior disorders that are comorbid
with ADHD are an important factor in determining the clinical picture. Adolescents diagnosed
with DBD and ADHD are at a higher risk of undergoing psychiatric hospitalization at some
time in their life [19].
The overlap of ADHD and conduct problems is explained by common genetic and non‐
shared environmental  factors  that  influence both disorders.  Nevertheless,  the two disor‐
ders  appear  to  be  partly  distinct,  in  that  additional  environmental  factors  influence  the
severity of the behavioral problems. It appears that ADHD+CD is a genetically more severe
variant of ADHD [20].
One study compared patients with ODD/CD, comorbid ADHD, and those with only
ODD/CD. Both the patient subgroups had deficits in visuospatial working memory compared
to the control subjects, indicating that children with ODD/CD have deficits in visuospatial
working memory that are independent of the comorbid ADHD, and that a deficient working
memory may be an underlying factor in the development of ODD/CD [21].
Two subtypes of ODD are associated with ADHD, one that is prodromal to CD and another
that is subsyndromal to ADHD and unlikely to progress into CD in the later years. These ODD
subtypes have different correlates, courses, and outcomes. In a large, well-characterized, cross-
sectional sample of children with ADHD assessed at baseline and 4 years later at midadoles‐
cence, Biederman et al. found that the majority of the children with ODD did not have
comorbid CD. In contrast, CD was almost always comorbid with ODD. When ODD co-
occurred with CD, it preceded the onset of CD by several years. These findings indicate that
the two subtypes of ODD within ADHD can be distinguished as either being prodromal to CD
or not. The study also found that CD and ODD had similar correlates, and that these were less
severe in children suffering from ODD than CD, thus supporting the initial hypothesis that
ODD is a subsyndromal form of CD. This notion assumes that both disorders are part of the
same disease process in which CD is the more severe form while ODD is the less severe form
of the same disorder. Their findings, that CD is almost always comorbid with and precede
ODD, are also consistent with the second hypothesis that a subtype of ODD is prodromal to
CD. This subtype differs from the other type of ODD in that there is significantly higher risk
of familial antisocial disorders, comorbidity with mood and anxiety disorders, earlier age at
onset of ODD, higher number of comorbid psychiatric disorders, and greater number of ODD
symptoms [22].
One study involving the long-term monitoring of CD and ODD patients identified an increased
risk of long-term depression in patients with ODD and comorbid ADHD. The same study also
reported that patients with accompanying CD are at risk of developing psychoactive substance
use disorders and bipolar disorder in the long term [23]. Increased conflict, impaired commu‐
nication, and incompatibilities between parents and the child also lead to an increased risk of
ODD and CD in adolescents with ADHD [24]. While ODD is a precursor of CD, certain
additional risk factors are required for ODD to progress to CD. The clinical features of young
people with CD include a predominance in males, low socioeconomic status, and familial
aggression [25]. Wilson and Morcotte divided ADHD patients aged between 14 and 18 years
into two groups as with or without CD and compared these two groups in terms of success at
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school, self-perception, behavior problems, alcohol and substance abuse, and adaptive
behaviors. They reported that patients with CD exhibit significantly lower rates of success in
school, greater externalizing behaviors and emotional difficulties, and lower adaptive
behaviors compared to patients without CD [26].
The response to treatment in patients with ODD and CD comorbid with ADHD may vary, and
there is a greater need for integrative therapeutic approaches in these cases. A higher dose of
ADHD drugs may be required, apart from combined drug use, particularly atypical antipsy‐
chotics. Atypical antipsychotics are very frequently used in patients exhibiting ADHD and
disruptive behavior, and studies have mainly focused on risperidone. One meta-analysis
published recently reported that among the atypical antipsychotics, risperidone has a positive
effect on aggression and behavioral disorders in the 5- to 18-year age-group; however, similar
data on other atypical antipsychotics are not available [27]. Another recent study also com‐
pared risperidone and placebo in 168 patients aged 6-12 years diagnosed with ADHD+ODD/
CD who were prescribed methylphenidate and a parental education program. A reduction in
aggression and attacks on peers was observed when risperidone was added, but it was not
particularly effective in relieving the symptoms of the behavior disorder [28]. One open study
from Turkey suggested that aripiprazole reduce anger and guilt in cases of ADHD+CD [29].
Nondrug therapies are of great importance in the treatment of ODD and CD, and multidi‐
mensional therapies are indicated since the basis of these conditions lie in familial dysfunction,
societal problems, and disorganized families. Studies have shown that parental education
programs, when combined with a behavioral approach, have a positive effect on children with
ODD with respect to nonrule governed actions, anger, and negativism. In addition, enrollment
in sports programs also has a positive effect on this group of patients [30], and patient
participation in other therapeutic approaches increases following an effective drug therapy.
3. Learning disorders
Learning disorder (LD) is a common comorbid condition in ADHD. One review of the studies
on ADHD/LD comorbidity conducted between 2001 and 2011 reported wide differences in
comorbidity rates, and rates of LD comorbidity in patients ranged between 8% and 76%.
Greater difficulties in writing, but not in reading or mathematics in particular, were reported
by the studies on patients with high comorbidity rates [31-33]. Morgan et al. [34] reported
that the type of mathematical learning disorder that is more common in cases with ADHD
is predominantly the inattentive type. The median prevalence rate of LD was 45% in another
study, indicating that, on an average, one out of every two children with ADHD also have
LD [35].
Several studies have investigated the etiology of ADHD+LD comorbidity, and structural and
functional neuroimaging studies, and behavioral, genetic, and molecular research has revealed
the existence of a complex relationship between these two disorders [36].
ADHD and LD share some common symptoms. For example, an attention deficit may have
an adverse effect on a child’s concentration and learning process. The inability to concentrate
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on details and making of careless errors also have a negative effect on knowledge acquisition
and accurate information gathering. Confusion between alphabets (such as between b and d
seen in children with a reading disorder) may also be seen in inattentive children. They may
also have difficulties in solving mathematical problems due to their inability to concentrate on
details and errors may occur while writing. Thus, children with a learning disorder are
reluctant to study because they cannot acquire effective reading, writing or mathematical
skills, and similarly, children with ADHD avoid tasks that require uninterrupted attention. As
children with a learning disorder have problems transferring information from their short-
term memory to their long-term memory and in processing that information, they may forget
the information after some time, thus feeling as if they had never acquired it to begin with.
Forgetfulness can also be seen in children with ADHD.
Academic difficulties associated with an attention deficit may increase over the course of time
in children with ADHD, and this can be confused with LD [37]. Symptoms of an attention
deficit in children with ADHD have an adverse impact on the learning processes and lead to
the clinical manifestation of learning disorders. If these two disorders are comorbid, then the
symptoms may follow a more severe course. Therefore, the presence of LD should be inves‐
tigated when ADHD is diagnosed, and a differential diagnosis should be performed.
Children with ADHD and LD together are also more resistant to treatment. Comorbid LD must
be considered in patients with ADHD who do not show improvement despite treatment. A 6-
week randomized, double-blinded, place-controlled study that compared the effectiveness of
methylphenidate in ADHD with or without comorbid LD reported that behavior and per‐
formance improved with oral methylphenidate in both the groups [38]. The effectiveness of
methylphenidate in alleviating the core symptoms of ADHD is clear, but there is insufficient
evidence supporting its efficacy in LD alone.
Another study assessed the response to atomoxetine therapy in ADHD and ADHD accompa‐
nied by dyslexia and reported a significant improvement in ADHD symptoms and reading
scores in both the groups. A correlation analysis performed in the same study showed that
improvement in reading was not by itself sufficient to account for the decrease in symptoms
of ADHD. Further research is needed to ascertain the potential effects of atomoxetine on
reading in children with ADHD+dyslexia or dyslexia alone [39].
Pharmacotherapy alone is insufficient to treat children with ADHD+LD. Psychological
therapies can be added to pharmacological treatment, but more research is required to clarify
their role in the treatment of ADHD and comorbid learning disability [40]. Special education
techniques also need to be used in such cases.
4. Intellectual disability
ADHD is a widespread clinical condition in individuals with intellectual disability (ID). One
study that investigated psychiatric comorbidities in groups with or without ID reported that
the greatest difference between the two groups was in the rate of meeting the diagnostic criteria
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for ADHD (ratio = 3.21:1). The same study also reported a correlation between high stability
of externalizing behavior problems at age 3 to a diagnosis of ADHD at age 5 in both the groups
[41]. Another longitudinal study investigated ADHD in children with or without accompa‐
nying ID and monitored these children from the age of 5 till the age of 8 years. ADHD was
three or more times prevalent in the ID group compared to typical development across ages
5, 6, 7, and 8 years, and ADHD tended to be diagnosed earlier and was more stable in the ID
group [42].
Children with ID exhibit a greater risk for developing ADHD, and the disorder may follow a
longer and more persistent course, apart from increasing the risk of developing further
psychiatric problems. These findings highlight the need for making available the interventions
necessary for early treatment of ADHD in children with ID.
One study on the effectiveness of stimulant drug therapy in children diagnosed with ADHD
and ID reported that the symptoms of ADHD could be successfully treated in children with
ADHD and ID [43]. A randomized, controlled, double-blind study of children with severe
ADHD and ID suggested that methylphenidate is effective in reducing the symptoms of
ADHD in these children [44]. Stimulants have a similar effect on improving impulsivity,
hyperactivity, and attention deficit in children with IQ ranging between 45 and 75 compared
to normal children; however, they may exhibit fewer improvements in learning and memory.
Stimulants appear to have a positive effect in preschool children, albeit with more side effects
[45]. Reduced appetite, nausea, and irritability are the most common adverse events reported
in children with developmental disabilities (DD); clinicians should be aware that, as with
stimulants, irritability appears to occur much more commonly in children with DD than in
normally developing children. Initial splitting of the dose, starting below the recommended
dose, and slowly titrating the dose may prevent or ameliorate these side effects [46].
Only one open-label study has investigated the effectiveness of atomoxetine (ATX) in children
with ADHD and ID not accompanied by the autism spectrum disorder (ASD). Atomoxetine
appears to be useful in improving ADHD symptoms in individuals with ID. Larger, random‐
ized, controlled, double-blind studies are required to confirm the efficacy of ATX in children
with ID without ASD [47].
Clinicians must carefully consider the following when treating cases of ID with ADHD. As
patients in this group may have a lower tolerance to side effects, greater care must be taken
during dose titration,  and drugs must  be started at  low doses and gradually increased.
Antipsychotic agents such as risperidone can lead to an improvement in irritability. Many
children with ID may have a micronutrient imbalance that could benefit from an RDA/RDI
multivitamin/mineral  supplement,  especially  if  appetite  has  been  suppressed  by  the
stimulant [48].
5. Depression and anxiety disorder
Prospective studies show that children and adolescents diagnosed with ADHD are also more
frequently diagnosed with major depressive disorder (MDD) compared to control subjects
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[49]. Additionally, ADHD is more common in children with major depressive disorder [50].
Studies that have investigated internalizing problems, such as depression and anxiety in the
subtypes of ADHD, have shown that internalizing problems are more common in the attention
deficit ADHD subtype [51]. CD and ODD seem to appear in early childhood in ADHD, while
the symptoms of depression and anxiety appear later [52].
Several studies have been performed to explain the etiology of comorbid ADHD and depres‐
sion. These studies have shown a genetic overlap between ADHD and depression, and both
disorders involve dopamine reward circuit problems and difficulty in emotional regulation.
A dysfunctional relationship with parents has also been shown to play a role in the etiology
of comorbidities in children with ADHD [51].
Symptoms of depression, such as sleep disorders, difficulty concentrating, and irritability, and
symptoms of anxiety disorders, such as sustained anxiety and failure to concentrate, may be
confused with ADHD and lead to a misdiagnosis. Depression or anxiety accompanying ADHD
make diagnosis difficult and result in greater severity of symptoms [53]. Depression is 2.5 times
more frequently diagnosed during adolescence and early adulthood in girls previously
diagnosed with ADHD, and the onset of depression is earlier and is more protracted. Depres‐
sion leads to greater depression-related loss in functionality, increases disposition to suicide,
and requires more hospitalization [54]. The adverse effect of comorbid ADHD on the prognosis
of depression and the higher incidence of attempted suicide in hyperactive young people make
the identification of comorbid depression and ADHD particularly important. It is also
important not to overlook the depressive disorder comorbidity in children diagnosed with
ADHD as the depressive disorder can increase the severity of attention problems in ADHD
[55]. One study showed that the probability of developing comorbid bipolar affective disorder
or major depression is higher in patients with ADHD than in patients suffering from major
depression alone [56]. One study, intended to determine which children with ADHD subse‐
quently develop depression, showed that ADHD patients with comorbid anxiety and/or
disruptive behavior disorders have a higher probability of developing depression [57].
Measures can be taken to avoid the development of depression in ADHD patients who are
diagnosed with comorbid anxiety and/or disruptive behavior disorders. While the existence
of anxiety in ADHD has an improving effect on DBD, performance anxiety and feelings of
inadequacy are thought to be more prominent [58]. Although anxiety reduces the inhibition
response in anxiety ADHD and impulsivity, it can worsen work memory test performance [59].
A detailed investigation of the psychiatric symptoms in the family will assist physicians with
the diagnosis and treatment of these patients.
Recent familial, genetic, and long-term follow-up studies have demonstrated that ADHD and
major depressive disorder share a common familial risk [60]. Comorbidity of ADHD and
emotional disorders (such as anxiety) determines the severity of the clinical symptoms and
leads to severe social maladaptations.
Since environmental factors make a significant contribution to the development of depression
in individuals with ADHD, overcoming these environmental factors and relational problems
is an important part of treatment. If the depressive symptoms are mild, treatment starts with
assuaging ADHD, and this itself frequently leads to a resolution of the depressive symptoms.
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If no improvement in the depressive symptoms is observed, SSRIs may be added. Appropriate
dosage and gradual titration are important when using SSRIs.
Depression-related nondrug therapies, particularly cognitive behavioral therapy, may be
started along with ADHD drugs in this group. One study on adolescents diagnosed with
depression compared the relative effectiveness of three therapeutic approaches, namely,
fluoxetine, CBT, and combined treatment, with a placebo. Only combined treatment emerged
superior to the placebo in patients with depression alone, but fluoxetine, CBT, and combined
treatment were all better than the placebo in adolescents with ADHD and comorbid MDD [61].
The form of treatment that should be undertaken when these disorders are comorbid with
ADHD is controversial, and the disorder dominating the general picture should be treated
primarily. If there is no doubt regarding the diagnosis of both disorders and the clinical picture
is sufficiently severe to require treatment, then such treatments may be started together.
Despite a scarcity of well-designed treatment studies in youth with ADHD and comorbid
depression, there is increasing preliminary evidence on the role of stimulants, selective
serotonergic reuptake inhibitors, bupropion, and atomoxetine in targeting either or both
disorders. There is also some indirect evidence on the benefits of combining pharmacological
treatments with psychosocial interventions that specifically target relevant environmental
factors and functional impairments [62].
In cases of comorbid ADHD and anxiety disorder, therapeutic priority is determined on the
basis of the severity of both disorders and the extent of their negative impact on life. If the
anxiety is not very severe, then priority must be attached to treating ADHD. In addition, if the
patient is amenable to psychotherapy, then this can also be recommended for improving the
anxiety disorder in parallel with ADHD treatment. If the anxiety disorder symptoms are very
severe, however, SSRIs must be added to the treatment regimen. CBT has been shown to be
effective in both adolescents and adults. In addition, psychosocial therapies should be advised
in patients with anxiety disorder [30].
6. Bipolar affective disorder (BAD)
Comorbidity or merging of ADHD and BAD is not yet fully understood. There are a number
of questions concerning the relationship between these two disorders, such as is there
symptomatic similarity between ADHD and BAD, is one a precursor of the other, are ADHD
and BAD familial subtypes, are there any similarities in terms of comorbidity and course?
The three symptoms sufficient for diagnosing a manic attack in children, namely, distractibil‐
ity, excessive talking, and hyperactivity, are also compatible with a diagnosis of ADHD, and
given these overlapping symptoms, it is possible that BAD may be misdiagnosed as ADHD
or vice versa. The rate of ADHD comorbidity in children diagnosed with BAD ranges from
11% to 98% [63], while BAD comorbidity is lower in individuals with ADHD. This variation
may be because ADHD is more commonly diagnosed in children rather than BAD. The
prevalence of ADHD in children is higher than BAD, and the predictors of bipolarity may not
be completely determined in the presence of comorbid ADHD.
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Biederman et al. [63] conducted a 4-year follow-up study and found that the rate of comorbid
bipolar disorder increased by an additional 12% at the end of the 4 years; 11% of the children
with ADHD had comorbid bipolar disorder at baseline, and these prevalence rates were
significantly higher compared to control groups without ADHD. Furthermore, significantly
higher rates of additional psychopathology, psychiatric hospitalization, and severely impaired
psychosocial functioning were observed in children with ADHD and comorbid BAD, com‐
pared to children with ADHD alone both at baseline and at follow-up assessment. The authors
also suggested that comorbid ADHD and bipolar disorder do not result from overlapping
symptoms.
Co-occurrence of these two disorders is associated with poorer global functioning, greater
symptom severity, and additional comorbidity compared to either disorder alone [64].
Available data strongly suggest that the prepubertal onset of BAD is a nonepisodic, chronic,
rapid-cycling, mixed manic state that may be comorbid with ADHD and CD [65]. Several
studies have reported that pediatric BAD is characterized by irritable and dysphoric moods,
mixed episodes, explosive behavior accompanied by anger attacks, and rapid and ultrarapid
cycling with a chronic course [66].
There is a significant loss of functionality in both the disorders. An investigation of the etiology
of these two disorders, their effective diagnosis, and treatment are important to keep this loss
in functionality to a minimum. One familial study that investigated comorbid ADHD and BAD
reported higher rates of ADHD diagnoses in families of subjects with BAD and higher rates
of BAD diagnosis in families of subjects diagnosed with ADHD [67]. In addition to genetic
factors, potential environmental risk factors for comorbidity have also been investigated [68].
As the presence of comorbidities has an adverse effect on the course of both disorders, early
identification and prompt treatment are critical. Different classes of psychopharmacological
medications  are  employed  in  the  treatment  of  ADHD and  BAD,  such  as  stimulants  or
atomoxetine  for  ADHD  and  mood  stabilizers  or  antipsychotics  for  mania.  Problems  in
differentiating between the two disorders and deciding on the best form of clinical manage‐
ment have important clinical implications for patients. Research also suggests that incor‐
rect treatment may result in nonresponsiveness or worsening of symptoms in the case of
ADHD and BAD [69].
7. Disruptive mood dysregulation disorder
Researchers regard emotional instability as a core deficit in children diagnosed with ADHD
[70]. Therefore, affective instability in children diagnosed with ADHD does not directly
indicate the presence of a comorbid mood disorder [71]. The National Institute of Mental
Health (NIMH) created a construct for Severe Mood Dysregulation (SMD) to describe such
children who do not meet the criteria for a formal mood disorder. Disruptive mood dysregu‐
lation disorder (DMDD) took its place in DSM V as a modification of SMD.
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ADHD, ODD, and CD are the most common accompanying Axis I diagnoses in children with
DMDD [72]. Children with ADHD and SMD experience greater morbidity than children with
externalizing behavior disorders alone and are in need of specialized treatment to optimize
their functioning [73]. Various behavior modifying therapies and stimulation therapy combi‐
nations have been developed for children with comorbid ADHD and SMD, and they have been
shown to be effective and acceptable. Research has repeatedly shown that subjects with a
diagnosis of SMD exhibited significantly higher levels of functional impairment after a 3-week
therapeutic process compared to those with no such diagnosis [74]. It is also important for the
parents of children with both these disorders to be referred to parenting programs and family
therapy. One study on children with both ADHD and SMD used stimulation therapy at
optimal doses prior to their randomization into two groups. One group received treatment
involving psychosocial measures for 11 weeks, while the other group took part in group
therapy. A significant decrease in suicidal ideation was observed in children receiving group
therapy, and their parents also exhibited a more positive parenting behavior [71].
To date, there are too few studies to establish a specific treatment guideline for SMDD. ADHD,
the prominent problem in comorbid ADHD and SMDD, can be improved with stimulation
therapy. Low-dose antipsychotics can be tried when the basic problems are arousal symptoms
and behavioral difficulties.
8. Alcohol and substance use disorder
Significantly high rates of development of substance use disorder (SUD), involving use of
nicotine, alcohol, marijuana, cocaine, or other drugs, during adolescence have been reported
in individuals diagnosed with childhood ADHD [75]. One 10-year study of patients with
ADHD showed that the probability of these patients developing substance dependence was
twice as high as that of the control group [76]. A study of comorbid psychiatric disorders in
subjects with substance abuse disorder reported that half of the adolescents aged under 15
years met the diagnostic criteria for ADHD [77]. Further, early onset and a more severe
substance use disorder have been correlated with ADHD. One recent meta-analysis found that
childhood ADHD is associated with nicotine use in adolescence and alcohol and drug use
disorder in adulthood [78].
As anxiety, depression, and aggression are frequently seen in children and adolescents with
ADHD, these patients use substances such as nicotine to self-treat symptoms of anxiety and
depression, and nicotine suppresses symptoms of ADHD. Thus, individuals with ADHD use
addictive substances to treat psychiatric comorbidities.
One twin study reported that a substance use disorder did not develop in subjects with ADHD
without CD [79]. In children diagnosed with ADHD, the group with comorbid CD and/or BAD
was at highest risk of developing a substance use disorder [80]. This marked association
between ADHD and substance use disorder shows the importance of diagnosing and treating
childhood ADHD to avoid the later development of a severe substance use disorder.
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In light of the high comorbidity between ADHD and substance use disorder, it is possible that
there are common underlying neurological factors, and ADHD and substance problems also
have several common causes.
Variations in dopamine genes that affect attention, arousal, and reinforcement sensitivity are
possible common risk factors for the development of ADHD and substance use disorder [81],
and altered dopamine (DA) neurotransmission is central to current models of how ADHD and
substance abuse disorder develop [82].
As substance abuse itself leads to changes in the brain, it is impossible to determine if indi‐
viduals with a substance use disorder also exhibit characteristics similar to ADHD or not.
However, the changes occurring in the brain due to a substance use disorder are thought to
make these individuals more inclined to engage in impulsive behavior, similar to individuals
with ADHD but before the onset of the disorder and before the substance abuse. A recent
review of neuroimaging studies in humans with ADHD and SUD found repeated evidence of
a blunted striatal DA release and a disruption in neural circuitry between the anterior cingulate
cortex, the striatum, and the prefrontal cortex. ADHD and SUD-related craving share some
neurobiological similarities, which may be because patients with an addiction show increased
craving if they also suffer from ADHD [83].
Recent studies have shown that effectively treating ADHD symptoms may be protective in
patients with a substance use disorder. The claim that treating ADHD symptoms with
stimulants increases the risk for future substance abuse has not been verified, and in fact, the
opposite effect is typically seen in medication-treated individuals. Children treated with
stimulants appear to have a significantly lower risk of developing a substance use disorder
than those who were not pharmacologically treated.
This finding suggests that ADHD does in fact contribute to the development and maintenance
of substance use problems, as the successful treatment of ADHD symptoms results in a
reduction of the substance use problem [84].
9. Developmental coordination disorder
Several studies show a high correlation between ADHD and developmental coordination
disorder (DCD). ADHD-DCD comorbidity can be as high as 50% in children [85]. In a study
of 477 cases of ADHD, Blondis et al. [86] have reported the presence of a comorbid develop‐
mental coordination disorder in at least 33% of the subjects.
Maladroitness in children with ADHD frequently decreases with age, and the children may
successfully engage in sporting activities. However, this does not occur in the presence of a
comorbid developmental coordination disorder, and it generally persists along with the
inattention [86]. Clinical research has shown that maladroitness, clumsiness, and ponderous‐
ness seriously affect a child in numerous areas, and that these children find it difficult to
perform certain activities at the same speed as their peers in school.
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The possible treatment consists of psychological and educational support. Tervo et al. [87]
compared the response to methylphenidate in subjects with developmental coordination
disorder and ADHD and ADHD alone. They reported that the response to the drug was similar
in both the groups and that the stimulant was also effective in treating ADHD.
There are two hypotheses concerning the decrease in symptoms following treatment with
methylphenidate. The first is that methylphenidate increases attention, and that increased
attention leads to an improvement in motor deficits, while the second is that drug therapy has
distinct effects on attention and motor skills.
The proportion of children with ADHD who could improve their motor skills to the normal
range upon medication varies from 28% to 67% among reported studies. While the symptoms
of patients with a mild motor deficit before treatment improve to normal levels with therapy,
in patients with a more severe motor deficit before treatment, the symptoms only decrease in
severity and they may still continue to meet the diagnostic criteria for DCD.
It is important to assess motor skills among children with ADHD because of the risk of their
reduced participation in daily activities that require motor coordination and attention [88].
10. Enuresis and encopresis
ADHD and incontinence are common diseases in childhood, are commonly seen together, and
also affect one another. Nocturnal enuresis (NE) is seen in 10% of children aged 7 years,
daytime urinary incontinence (DUI) in 2-3% and fecal incontinence (FI), or encopresis in 1-3%.
Baeyens et al. [89] have investigated the prevalence of ADHD in 120 children with primary
enuresis using parent and teacher questionnaires and diagnostic interviews. Their results
indicate that 15% of the children met the criteria for ADHD, and a further 22.5% of them met
the criteria for the ADHD inattentive type. A 2-year follow-up study of the same cohort
indicated that 73% of those initially diagnosed with ADHD had the diagnosis reconfirmed at
follow-up [90]. The authors also noted that the probability of a child with ADHD still having
episodes of nocturnal enuresis at 2-year follow-up were 3.2 times higher than that for a child
who did not have comorbid ADHD.
There are several hypotheses to explain the comorbidity of ADHD and NE. There is evidence
that genetic factors occupy an important place in the etiology of ADHD and NE, as the
heritability of NE and ADHD as individual disorders is high. However, the only formal
molecular genetics study on both the disorders indicates that NE and ADHD are genetically
independent, separate entities that do not share a common genetic basis.
Neuroimaging studies have established a great overlap in brain structures involved in ADHD
and NE (and to a lesser extent in DUI and FI); however, a possible interaction between
functional brain activity in combined incontinence and ADHD has not yet been studied. It is
therefore unclear why and how ADHD and incontinence together affect central nervous
system (CNS) functioning. From the few studies on ADHD and NE, it can be speculated that
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complex neural networks, including cortical, subcortical, and brainstem regions, will most
likely be responsible for the clinically evident interaction effects [91].
Incontinence must be investigated in children with ADHD, and ADHD must be investigated
in children with incontinence. The management of enuresis includes supportive approaches
such as educating parents about enuresis, reducing fluids, keeping a dry bed chart, and
awakening the child to void during the night, conditioning with a urine alarm, or medications
such as imipramine or desmopressin acetate [92]. Treatment must be adapted to include both
supportive approaches and pharmacotherapy in patients with ADHD and incontinence.
One double-blind, placebo-controlled study investigating the effectiveness of atomoxetine in
children with NE reported a significant decrease in symptoms. Atomoxetine, a highly specific
inhibitor of the presynaptic norepinephrine transporter, increases the effects of norepinephrine
in many brain areas. Atomoxetine-mediated decrease in symptoms of NE supports the
hypothesis that these drugs, with their noradrenergic effect, may be beneficial in the treatment
of this disease [93]. NE and ADHD may improve with both methylphenidate and atomoxetine.
Many hypotheses have been proposed—involving central neurochemical dysfunctions
(dopaminergic and noradrenergic), anticholinergic, and reduced sleep arousal effects of these
drugs—to account for the effects of these medications in the treatment of enuresis and ADHD
[94, 95].
Studies aimed at understanding the relationship between ADHD and elimination disorders
may identify common, underlying neurological alterations that may lead to a more effective
treatment for both the disorders [96].
11. Tic disorders
Tic disorders are quite rare in the general population but are common in the population with
ADHD. Tic comorbidity in patients with ADHD ranges between 8% and 10% [97, 98], and
ADHD is the most common accompanying disorder in tic patients [99].
Tic disorders have little effect on the psychosocial functioning of subjects with ADHD [100].
There is no definitive evidence regarding the course of ADHD being affected by the tic
disorder. However, accompanying obsessive-compulsive symptoms have been reported in a
significant proportion of individuals with ADHD and comorbid tic disorders. Tics, OCD, and
ADHD are related in a number of complex ways and have common demographic and
psychopathological risk factors [101].
Greater psychopathology and social and academic impairment have been reported when
ADHD is comorbid with Tourette’s disease [102]. Earlier age at onset, greater difficulty of anger
control, sleep problems, ODD, mood disorders, deficient social skills, inappropriate sexual
behavior, and self-harming behaviors are seen when Tourette’s syndrome is comorbid with
ADHD [103].
The pathophysiology of ADHD and the tic disorder is unclear, although their comorbidity
suggests that they have similar mechanisms or at least that they are compatible to varying
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degrees [104]. These two disorders share a number of genetic, neuronal, and cognitive risk
factors, and several dopamine and serotonin genes have been studied as potential risk factors.
Genes and environmental risk factors are also thought to cause both disorders. Abnormalities
in the same anatomical cycle, such as cortical thinning, frontal system abnormalities, and basal
ganglia abnormalities, have been shown in children with Tourette’s and ADHD [105].
A comprehensive treatment program for Tourette’s syndrome and comorbid ADHD should
include measures other than medication such as cognitive-behavioral, psychoeducational, and
psychosocial interventions.
Three classes of drugs are currently used in the treatment of Tourette’s syndrome and
comorbid ADHD: α-agonists (clonidine and guanfacine), stimulants (amphetamine enantiom‐
ers, methylphenidate enantiomers or slow release preparations), and selective norepinephrine
reuptake inhibitors (atomoxetine). It has been recently suggested that in a few selected cases
partial dopamine agonists (aripiprazole) could be useful, and there is evidence supporting the
use of noradrenergic agents (clonidine). Reuptake inhibitors (atomoxetine) and stimulants
(methylphenidate) could also be used for the treatment of Tourette’s syndrome and comorbid
ADHD [106]. Although the evidence is insufficient, there are studies that suggest using
aripiprazole in children with mild ADHD [107].
12. Conclusion
ADHD is associated with several comorbid psychiatric diseases and conditions, and these
comorbid conditions may cause a worsening of the symptoms of ADHD. Greater loss of
functionality is observed in patients with a comorbid condition. It is important to diagnose
and treat these comorbid conditions to effectively treat ADHD.
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